Abstract
Daily injections of high dose human recombinant interleukin-1 beta (IL-1 beta) accelerated the onset of both insulin-dependent diabetes mellitus and lymphocytic thyroiditis in genetically prone BB rats. In diabetes-resistant BB rats, high dose IL-1 beta failed to induce diabetes. Additionally, the presence of neutralizing IL-1 beta antibodies in these rats strongly correlated with inhibition of lymphocytic thyroiditis. Since low dose IL-1 beta protects diabetes-prone rats from IDDM, we conclude that IL-1 beta is a potent modulator of autoimmune diabetes and thyroid disease in genetically susceptible rats.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adrenal Glands / anatomy & histology
-
Age Factors
-
Animals
-
Autoimmunity*
-
Diabetes Mellitus, Type 1 / chemically induced
-
Diabetes Mellitus, Type 1 / immunology
-
Dose-Response Relationship, Drug
-
Enzyme-Linked Immunosorbent Assay
-
Germ-Free Life
-
Injections, Intraperitoneal
-
Interleukin-1 / pharmacology*
-
Islets of Langerhans / immunology*
-
Kidney / anatomy & histology
-
Male
-
Organ Size / drug effects
-
Pancreas / anatomy & histology
-
Rats
-
Rats, Inbred BB
-
Recombinant Proteins / immunology
-
Spleen / anatomy & histology
-
Thymus Gland / anatomy & histology
-
Thyroid Gland / anatomy & histology
-
Thyroid Gland / immunology*
-
Thyroiditis, Autoimmune / chemically induced
-
Thyroiditis, Autoimmune / immunology
-
Thyroxine / blood
Substances
-
Interleukin-1
-
Recombinant Proteins
-
Thyroxine